Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
37
datasets available to search
ShareScore release 0.9.0
Dataset results
37 results for “Antithrombin”
Raw data for the article: A Randomized Controlled Trial of Antithrombin Supplementation During Extracorporeal Membrane Oxygenation
<p><strong>Objectives: </strong>Supplementation of antithrombin might decrease the amount of heparin needed to achieve a given anticoagulation target during extracorporeal membrane oxygenation. However, exogenous antithrombin itself may increase the risk of bleeding. We conceived a study to evaluate the effect of antithrombin supplementation in adult patients requiring venovenous extracorporeal membrane oxygenation for respiratory failure on heparin dose, adequacy of anticoagulation, and safety.</p> <p><strong>Design: </strong>Prospective randomized controlled trial.</p> <p><strong>Setting: </strong>ICUs of two Italian referral extracorporeal membrane oxygenation centers.</p> <p><strong>Patients: </strong>Adult patients requiring venovenous extracorporeal membrane oxygenation for severe respiratory failure and unfractionated heparin for systemic anticoagulation.</p> <p><strong>Interventions: </strong>Before extracorporeal membrane oxygenation start, patients were randomized to either receive antithrombin concentrate to maintain a plasmatic level 80-120% (treatment) or not (control) during the extracorporeal membrane oxygenation course.</p> <p><strong>Measurements and main results: </strong>The primary outcome was the total amount of heparin required to maintain activated partial thromboplastin time ratio 1.5-2. Secondary outcomes were anti-factor Xa, the incidence of hemorrhagic and thrombotic events, and the amount of blood products transfused. Twenty-four patients in the treatment group and 24 in the control group were included in the intention-to-treat analysis. Antithrombin was 109.5% (93.0-123.0%) in the treatment group and 84.0% (68.5-98.0%) in the control group (p = 0.001). Supplementation of antithrombin did not decrease heparin dose (13.5 international units/kg/hr [9.6-17.9 international units/kg/hr] vs 15.1 international units/kg/hr [10.7-18.3 international units/kg/hr] in the treatment and control group, respectively; p = 0.33) and anti-Factor Xa levels (0.4 international units/mL [0.3-0.5 international units/mL] vs 0.3 international units/mL [0.2-0.5 international units/mL] in the treatment group and control group respectively; p = 0.65). Bleeding, blood product transfusions, and thrombosis were not different in the two groups.</p> <p><strong>Conclusions: </strong>Antithrombin supplementation may not decrease heparin requirement nor diminish the incidence of bleeding and/or thrombosis in adult patients on venovenous extracorporeal membrane oxygenation.</p>
Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.
ClinicalTrials.gov study NCT00056550. IPD Sharing: Not stated. Countries: 6. Publications: 1.
Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia
ClinicalTrials.gov study NCT02059135. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery
ClinicalTrials.gov study NCT00110513. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass
ClinicalTrials.gov study NCT02037555. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass
ClinicalTrials.gov study NCT00823082. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Antithrombin III in Infectious Disease Caused by COVID-19
ClinicalTrials.gov study NCT04899232. IPD Sharing: NO. Countries: 1. Publications: 1.
Prevention of Thrombosis Recurrence in Patients With Low Circulating Levels of Antithrombin.
ClinicalTrials.gov study NCT01382550. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support
ClinicalTrials.gov study NCT02631174. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates
ClinicalTrials.gov study NCT01158729. IPD Sharing: Not stated. Countries: 1. Publications: 21.
Antithrombin III and Post-liver Transplantation Acute Kidney Injury
ClinicalTrials.gov study NCT04912193. IPD Sharing: YES. Countries: 1. Publications: 5.
Study to Assess the Prognostic Value of the Antithrombin III in the Acute Pancreatitis (AT-PROPANC)
ClinicalTrials.gov study NCT02373293. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Prospective Investigation of Antithrombin III Deficiency in Adult Patients With ECMO
ClinicalTrials.gov study NCT04879550. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III
ClinicalTrials.gov study NCT00846274. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Antithrombin Supplementation in ECMO
ClinicalTrials.gov study NCT03208270. IPD Sharing: NO. Countries: 1. Publications: 2.
Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia
ClinicalTrials.gov study NCT07036809. IPD Sharing: YES. Countries: 1. Publications: 0.
Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery
ClinicalTrials.gov study NCT01547728. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
ClinicalTrials.gov study NCT05794165. IPD Sharing: NO. Countries: 1. Publications: 0.
Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery
ClinicalTrials.gov study NCT01201070. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
ClinicalTrials.gov study NCT06096116. IPD Sharing: NO. Countries: 9. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.